Clinical Trial Detail

NCT ID NCT02035137
Title 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New Approaches to Neuroblastoma Therapy Consortium
Indications

neuroblastoma

Therapies

131I-MIBG

131I-MIBG + Irinotecan + Vincristine Sulfate

131I-MIBG + Vorinostat

Age Groups: adult child

No variant requirements are available.